How will HPV vaccines affect cervical cancer?

Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with 'high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.

[1]  D. McCance Human Papillomaviruses and Cell Signaling , 2005, Science's STKE.

[2]  D. Lowy,et al.  L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. , 1998, Virology.

[3]  D. Parkin,et al.  Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening. , 2006, Gynecologic oncology.

[4]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[5]  P. Lambert Papillomavirus DNA replication , 1991, Journal of virology.

[6]  M. Sapp,et al.  Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. , 2001, Virology.

[7]  Geoffrey P Garnett,et al.  Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. , 2005, The Journal of infectious diseases.

[8]  H. Hausen Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[9]  M. Lehtinen,et al.  Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses , 2006, PLoS medicine.

[10]  S. Akira,et al.  Papillomavirus Capsid Mutation To Escape Dendritic Cell-Dependent Innate Immunity in Cervical Cancer , 2005, Journal of Virology.

[11]  P. Rous,et al.  THE PROGRESSION TO CARCINOMA OF VIRUS-INDUCED RABBIT PAPILLOMAS (SHOPE) , 1935, The Journal of experimental medicine.

[12]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[13]  A. Giuliano,et al.  A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. , 2004, Vaccine.

[14]  L. Brinton,et al.  Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  R. Schlegel,et al.  A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. , 1994, Pathobiology : journal of immunopathology, molecular and cellular biology.

[16]  D. Lowy,et al.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. , 2000, Virology.

[17]  R. Schlegel,et al.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Lowy,et al.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. , 1996, Virology.

[19]  I. Melo-Martín The Promise of the Human Papillomavirus Vaccine Does Not Confer Immunity Against Ethical Reflection , 2006 .

[20]  D. Lowy,et al.  HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. , 1989, The EMBO journal.

[21]  R. Zimmerman Ethical analysis of HPV vaccine policy options. , 2006, Vaccine.

[22]  D. Solomon,et al.  From Papanicolaou to Bethesda: The rationale for a new cervical cytologic classification , 1991, Obstetrics and gynecology.

[23]  M. Li,et al.  Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly , 1997, Journal of virology.

[24]  C. Wheeler,et al.  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.

[25]  C. Meyers,et al.  Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. , 1992, Science.

[26]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[27]  S. Szu,et al.  Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. , 1995, The Journal of infectious diseases.

[28]  N. Christensen,et al.  Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein , 2002, Journal of Virology.

[29]  Darren W. Henderson,et al.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins , 1994, Journal of virology.

[30]  J. Dillner,et al.  Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. , 1999, The Journal of general virology.

[31]  I. Frazer,et al.  HPV6b virus like particles are potent immunogens without adjuvant in man. , 2000, Vaccine.

[32]  C. Berkower,et al.  Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. , 2006, Vaccine.

[33]  S. H. van der Burg,et al.  Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination , 2004, Clinical Cancer Research.

[34]  T. Sasagawa,et al.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6and Type 16 in fission yeast Schizosaccharomyces pombe , 1995 .

[35]  P. De Grandi,et al.  Improved Efficiency of a Salmonella-Based Vaccine against Human Papillomavirus Type 16 Virus-Like Particles Achieved by Using a Codon-Optimized Version of L1 , 2004, Journal of Virology.

[36]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[37]  P. Dorian,et al.  Canine Model , 2005 .

[38]  Milton C Weinstein,et al.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.

[39]  Y. L. Lin,et al.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product , 1993, Journal of virology.

[40]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[41]  D. Lowy,et al.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype , 1996, Journal of virology.

[42]  D. Lowy,et al.  Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles , 2004 .

[43]  R. Garcea,et al.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles , 1993, Journal of virology.

[44]  W. White,et al.  A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. , 2001, The Journal of infectious diseases.

[45]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[46]  J. Palefsky Human papillomavirus‐associated malignancies in HIV‐positive men and women , 1995, Current opinion in oncology.

[47]  F. X. Bosch,et al.  Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV-positive human cell lines , 1991, Journal of virology.

[48]  K. Holmes,et al.  Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women , 2006, The New England journal of medicine.

[49]  Eto,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[50]  R. Shope IMMUNIZATION OF RABBITS TO INFECTIOUS PAPILLOMATOSIS , 1937, The Journal of experimental medicine.

[51]  R. Garcea,et al.  Immunization with a Pentameric L1 Fusion Protein Protects against Papillomavirus Infection , 2001, Journal of Virology.

[52]  D. Lowy,et al.  Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. , 2005, Vaccine.

[53]  M. Grace,et al.  Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.

[54]  J. Palefsky,et al.  A review of human papillomavirus vaccines: from basic science to clinical trials. , 2003, Frontiers in bioscience : a journal and virtual library.

[55]  D. Lowy,et al.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope , 1997, Journal of virology.

[56]  H. Schild,et al.  Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod1 , 2005, The Journal of Immunology.

[57]  R. Hoover,et al.  Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.

[58]  Margaret E McLaughlin-Drubin,et al.  Evidence for the coexistence of two genital HPV types within the same host cell in vitro. , 2004, Virology.

[59]  M. Campo,et al.  Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination , 1990, Veterinary Record.

[60]  Mark Schiffman,et al.  The promise of global cervical-cancer prevention. , 2005, The New England journal of medicine.

[61]  Claude Fauquet,et al.  Classification of papillomaviruses. , 2004, Virology.

[62]  David R. Scott,et al.  A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. , 2001, The Journal of infectious diseases.

[63]  R. Karron,et al.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.

[64]  B. Evans,et al.  Effect of local infection and oral contraception on immunoglobulin levels in cervical mucus , 1975, Infection and immunity.

[65]  R. Reichman,et al.  Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs. , 1992, The Journal of infectious diseases.

[66]  D. Lowy,et al.  NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. , 2001, Virology.

[67]  D. Lowy,et al.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. , 1994, Journal of the National Cancer Institute.

[68]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[69]  N. Christensen,et al.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus , 1996, Journal of virology.

[70]  R. Roden,et al.  Mucosal but Not Parenteral Immunization with Purified Human Papillomavirus Type 16 Virus-Like Particles Induces Neutralizing Titers of Antibodies throughout the Estrous Cycle of Mice , 1999, Journal of Virology.

[71]  R. Schlegel,et al.  Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. , 1994, Virology.

[72]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[73]  G. Garnett,et al.  Public health paradoxes and the epidemiological impact of an HPV vaccine. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[74]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[75]  G. Grindlay,et al.  Prophylactic and therapeutic vaccination against a mucosal papillomavirus. , 1993, The Journal of general virology.

[76]  W. White,et al.  Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies , 1998, Journal of Virology.

[77]  T. Wright,et al.  Women's desired information about human papillomavirus , 2004, Cancer.

[78]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[79]  D. Lowy,et al.  Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition , 1996, Journal of virology.

[80]  R. Reichman,et al.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. , 1994, The Journal of general virology.

[81]  A. Roberts,et al.  Intranasal Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing Cottontail Rabbit Papillomavirus L1 Protein Provides Complete Protection against Papillomavirus-Induced Disease , 2002, Journal of Virology.

[82]  J. Brandsma Animal models of human-papillomavirus-associated oncogenesis. , 1994, Intervirology.

[83]  Olivia Keiser,et al.  Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. , 2005, Journal of the National Cancer Institute.

[84]  G. Ruiz-Palacios,et al.  Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses , 2006, AIDS research and therapy.

[85]  N. Christensen,et al.  Antibody-mediated neutralization in vivo of infectious papillomaviruses , 1990, Journal of virology.

[86]  G. Hartmann,et al.  Activation of Dendritic Cells and Induction of T Cell Responses by Hpv 16 L1/E7 Chimeric Virus-Like Particles are Enhanced by Cpg ODN or Sorbitol , 2004, Antiviral therapy.

[87]  S. H. van der Burg,et al.  Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. , 2002, Vaccine.

[88]  W. White,et al.  In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16 , 1998, Journal of Virology.

[89]  S. Piantadosi,et al.  Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype , 2005, Clinical Cancer Research.

[90]  R. Schlegel,et al.  HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. , 1992, Virology.

[91]  N. Christensen,et al.  The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. , 1991, Virology.

[92]  D. Lowy,et al.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[93]  D. DiMaio,et al.  Rapid induction of senescence in human cervical carcinoma cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[94]  L. Koller,et al.  Attempted transmission of warts from man, cattle, and horses and of deer fibroma, to selected hosts. , 1972, The Journal of investigative dermatology.

[95]  S. Harrison,et al.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. , 2000, Molecular cell.

[96]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[97]  D. Lowy,et al.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. , 2003, Journal of the National Cancer Institute.

[98]  T. Rohan,et al.  Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. , 1999, Journal of the National Cancer Institute.

[99]  M. Schiff,et al.  Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. , 2004, Vaccine.

[100]  S. Marshall,et al.  Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus , 2006, International journal of cancer.

[101]  James P. Hughes,et al.  The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine , 2002, Epidemiology.

[102]  J. Dillner,et al.  Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. , 1995, Virology.

[103]  Daron G Ferris,et al.  Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial , 2005 .

[104]  R. Woods,et al.  Characterization of a Major Neutralizing Epitope on Human Papillomavirus Type 16 L1 , 1999, Journal of Virology.

[105]  Y. L. Lin,et al.  Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. , 1992, Virology.

[106]  R. Steinbrook The potential of human papillomavirus vaccines. , 2006, The New England journal of medicine.

[107]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[108]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[109]  R. Curtiss,et al.  Immunogenicity against Human Papillomavirus Type 16 Virus-Like Particles Is Strongly Enhanced by the PhoPc Phenotype in Salmonella enterica Serovar Typhimurium , 2004, Infection and Immunity.

[110]  R. Roden,et al.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice , 1997, Infection and immunity.

[111]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[112]  D. Lowy,et al.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection , 1995, Journal of virology.

[113]  D. Lowy,et al.  A quantitative in vitro focus assay for bovine papilloma virus. , 1980, Virology.

[114]  M. Hagensee,et al.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.

[115]  D. Lowy,et al.  Interaction of papillomaviruses with the cell surface , 1994, Journal of virology.

[116]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.